Sequencing of Agents for Castration-Resistant Prostate Cancer

In this review we will outline an approach to sequencing new therapies for metastatic castration-resistant prostate cancer (CRPC), with particular attention paid to the biology of CRPC.

Genitourinary Cancers

Study: Primary ADT Not Effective in Localized Prostate Cancer

Anna Azvolinsky, PhD

News | April 19, 2014 | Prostate Cancer, Genitourinary Cancers

By Anna Azvolinsky, PhD

Patients with localized prostate cancer treated with primary androgen deprivation therapy (ADT) without radiation therapy or surgery derived no survival benefit, according to the results of a large study.

Gemcitabine-Containing Combo Increased Complete Response in Germ Cell Tumors

Leah Lawrence

News | April 16, 2014 | Genitourinary Cancers, Testicular Cancer

By Leah Lawrence

The addition of gemcitabine to a cisplatin- and ifosfamide-containing drug regimen resulted in a complete response rate of greater than 50% in patients with relapsed metastatic germ cell tumors, results of a phase II study indicated.

Large Renal Mass: A Challenge for the Urologist

Rodrigo Donalisio Da Silva, MD

Wilson R. Molina, MD

Diedra Gustafson

Case Studies | April 15, 2014 | Oncology Journal, Genitourinary Cancers, Kidney Cancer

By Rodrigo Donalisio Da Silva, MD, Wilson R. Molina, MD, Diedra Gustafson, Leticia Nogueira, Shalini Tayal, MD, Francisco G. La Rosa, MD, and Fernando J. Kim, MD

A 60-year-old man was incidentally found to have a large right renal mass during a CT scan with and without intravenous and oral contrast ordered by his primary care physician to evaluate mild right side abdominal discomfort and hepatomegaly.

Palliative Radiotherapy for Prostate Cancer

Matthew J. Boyer, MD, PhD

Joseph K. Salama, MD

W. Robert Lee, MD, MS, MEd

Review Article | April 15, 2014 | Oncology Journal, Bone Metastases, Genitourinary Cancers, Prostate Cancer

By Matthew J. Boyer, MD, PhD, Joseph K. Salama, MD, and W. Robert Lee, MD, MS, MEd

This review will include discussion of the role of radiation therapy for osseous metastases and metastatic spinal cord compression, as well as the use of radiopharmaceuticals for painful osseous metastases.

Palliative Radiotherapy for Prostate Cancer: Encouraging Single-Fraction Radiotherapy

Lauren Hertan, MD

Joshua A. Jones, MD, MA

April 15, 2014 | Oncology Journal, Bone Metastases, Genitourinary Cancers, Prostate Cancer

By Lauren Hertan, MD and Joshua A. Jones, MD, MA

As new data and new treatment options emerge, palliative radiotherapy algorithms will need to undergo continuous modifications and updates to ensure that patients receive optimal symptom relief.

Palliative RT Research in Prostate Cancer: Understanding the Past, Anticipating the Future

Kristopher Dennis, MD, FRCPC

Scott C. Morgan, MD, MSc, FRCPC

April 15, 2014 | Oncology Journal, Bone Metastases, Genitourinary Cancers, Prostate Cancer

By Kristopher Dennis, MD, FRCPC and Scott C. Morgan, MD, MSc, FRCPC

Moving forward, perhaps no recent development in the use of RT in metastatic prostate cancer has captured greater attention than the use of radium-223 in metastatic castration-resistant prostate cancer (mCRPC).

The Daily Miracle of Palliative Radiotherapy for Prostate Cancer

James B. Yu, MD

April 15, 2014 | Oncology Journal, Genitourinary Cancers, Prostate Cancer, Radiation Oncology

By James B. Yu, MD

It is important for all of us now and then to take a step back and recapture the wonder that we all felt at the onset of our careers, when treatments we now consider simple and routine held an aura of miracle. For me, a little bit of that wonder returns every time I treat a patient with a bony metastasis—in particular, from prostate cancer.

Pages

Videos
Podcasts

Recurrence and Relapse in Testicular Cancer
Bruce Roth, MD
August 09, 2013 | Testicular Cancer, Genitourinary Cancers
By Bruce Roth, MD
Dr. Bruce Roth, Siteman Cancer Center, spoke at the 2013 ASCO meeting about topics in seminoma. Here he discusses recurrence, relapse, and seminomatous vs nonseminomatous testicular cancer.
Epidemiology of Seminoma
Bruce Roth, MD
August 09, 2013 | Testicular Cancer, Genitourinary Cancers
By Bruce Roth, MD
Dr. Bruce Roth, Professor of Oncology in the Division of Medicine at Siteman Cancer Center, Washington University at St. Louis, spoke at the 2013 ASCO meeting about topics in seminoma. Here he discusses the epidemiology of seminoma.
Surveillance for Stage I Seminoma: Part II
Bruce Roth, MD
News | August 09, 2013 | Testicular Cancer, Genitourinary Cancers
By Bruce Roth, MD
Dr. Bruce Roth discusses the large Danish study reported at ASCO (abstract 4502) that showed surveillance alone is sufficient after orchiectomy for stage I seminoma, focusing on its impact on post-surgery radiation therapy in this setting.
Surveillance for Stage I Seminoma: Part I
Bruce Roth, MD
August 09, 2013 | Testicular Cancer, Genitourinary Cancers
By Bruce Roth, MD
Dr. Bruce Roth discusses the large Danish study reported at ASCO (abstract 4502) that showed surveillance alone is sufficient after orchiectomy for stage I seminoma.